Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan

Abstract

Introduction: Pangenotypic direct-acting antivirals are expected to cure hepatitis C virus (HCV) in more than 95% of treated patients. However, data on the effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) in Taiwan are limited. This study aims to characterize the patient population in the nationwide Taiwan Association for the Study of the Liver (TASL) HCV Registry and evaluate treatment outcome in Taiwanese patients receiving SOF/VEL.

Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry

“…However, large-scale real-world data on this topic are scarce, especially in the Asian population. In the present study, we reported the real-world effectiveness and safety of the 8-week GLE/PIB regimen in treatment-naïve Taiwanese patients with HCV and compensated cirrhosis using the nationwide data from Taiwan Association for the Study of the Liver (TASL) HCV Registry (TACR) program [ 16 , 26 , 27 ].…”

Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting

“…The excellent broad-spectrum antiviral activity, negligible side effects, and simple once-daily dosage of pangenotypic DAA combination regimens simplify health care service delivery and can help accelerate the realization of the HCV elimination goals [ 16 ]. Large-scale real-world data from Taiwan also supported the excellent effectiveness and safety profiles of both first-line pangenotypic DAAs, namely GLE/PIB and sofosbuvir/velpatasvir (SOF/VEL) [ 7 , 17 – 20 ]. Shortening DAA treatment time regardless of cirrhosis status can further simplify HCV care, which may increase the number of health care professionals who can prescribe DAA regimens and increase the number of patients receiving treatment [ 10 , 11 ].…”

“…The excellent broad-spectrum antiviral activity, negligible side effects, and simple once-daily dosage of pangenotypic DAA combination regimens simplify health care service delivery and can help accelerate the realization of the HCV elimination goals [16]. Large-scale real-world data from Taiwan also supported the excellent effectiveness and safety profiles of both firstline pangenotypic DAAs, namely GLE/PIB and sofosbuvir/velpatasvir (SOF/VEL) [7,[17][18][19][20].…”

A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD

“…We found 22 studies that reported on specific DAA regimens in patients with CKD G4–G5ND (eGFR <30 ml/min per 1.73 m 2 , not on dialysis). 9 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 The studies evaluated the following: DCV/ASV (1 study, N = 10), GLE/PIB (4 studies, N = 149), GZR/EBR (5 studies, N = 857), PrO±D (5 studies, N = 153), SOF (2 studies, N = 41), SOF/DCV (4 studies, N = 571), SOF/LDV (2 studies, N = 43), SOF/SIM (1 study, N = 41), and SOF/VEL (2 studies, N = 99). Conclusions pertaining to DAA treatment in patients in CKD G4–G5ND are summarized in Table 1 .…”

“…Across 3817 patients, only 35 were on peritoneal dialysis. 9 , 22 , 23 , 24 , 26 , 29 , 30 , 31 , 34 , 37 , 38 , 39 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 The s...…”